JP6820838B2 - 乳癌発症リスクを評価する方法 - Google Patents
乳癌発症リスクを評価する方法 Download PDFInfo
- Publication number
- JP6820838B2 JP6820838B2 JP2017517098A JP2017517098A JP6820838B2 JP 6820838 B2 JP6820838 B2 JP 6820838B2 JP 2017517098 A JP2017517098 A JP 2017517098A JP 2017517098 A JP2017517098 A JP 2017517098A JP 6820838 B2 JP6820838 B2 JP 6820838B2
- Authority
- JP
- Japan
- Prior art keywords
- risk
- single nucleotide
- breast cancer
- nucleotide polymorphisms
- snp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010006187 Breast cancer Diseases 0.000 title claims description 210
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 210
- 239000002773 nucleotide Substances 0.000 claims description 167
- 125000003729 nucleotide group Chemical group 0.000 claims description 167
- 238000000034 method Methods 0.000 claims description 158
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 136
- 238000012502 risk assessment Methods 0.000 claims description 86
- 230000002068 genetic effect Effects 0.000 claims description 64
- 239000000523 sample Substances 0.000 claims description 62
- 150000007523 nucleic acids Chemical class 0.000 claims description 57
- 102000039446 nucleic acids Human genes 0.000 claims description 54
- 108020004707 nucleic acids Proteins 0.000 claims description 54
- 239000012472 biological sample Substances 0.000 claims description 10
- 238000003500 gene array Methods 0.000 claims description 6
- 108700028369 Alleles Proteins 0.000 description 54
- 239000013615 primer Substances 0.000 description 39
- 206010028980 Neoplasm Diseases 0.000 description 34
- 201000011510 cancer Diseases 0.000 description 30
- 238000001514 detection method Methods 0.000 description 30
- 239000003550 marker Substances 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 239000003814 drug Substances 0.000 description 28
- 229940124597 therapeutic agent Drugs 0.000 description 28
- 238000012216 screening Methods 0.000 description 23
- 230000003321 amplification Effects 0.000 description 19
- 238000003199 nucleic acid amplification method Methods 0.000 description 19
- 210000000481 breast Anatomy 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 108091093088 Amplicon Proteins 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 102000015694 estrogen receptors Human genes 0.000 description 12
- 108010038795 estrogen receptors Proteins 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 102000036365 BRCA1 Human genes 0.000 description 11
- 108700020463 BRCA1 Proteins 0.000 description 11
- 101150072950 BRCA1 gene Proteins 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 11
- 102000052609 BRCA2 Human genes 0.000 description 10
- 108700020462 BRCA2 Proteins 0.000 description 10
- 101150008921 Brca2 gene Proteins 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000012830 cancer therapeutic Substances 0.000 description 9
- 240000002853 Nelumbo nucifera Species 0.000 description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000035606 childbirth Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- -1 DNA Chemical class 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000007614 genetic variation Effects 0.000 description 5
- 208000030776 invasive breast carcinoma Diseases 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 238000013058 risk prediction model Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000009247 menarche Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003886 aromatase inhibitor Substances 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002113 chemopreventative effect Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000013179 statistical model Methods 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000012627 chemopreventive agent Substances 0.000 description 2
- 229940124443 chemopreventive agent Drugs 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 229960004421 formestane Drugs 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 102000000872 ATM Human genes 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000026535 luminal A breast carcinoma Diseases 0.000 description 1
- 208000026534 luminal B breast carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000010700 sporadic breast cancer Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014903898 | 2014-09-30 | ||
| AU2014903898A AU2014903898A0 (en) | 2014-09-30 | Methods for assessing the risk of developing breast cancer | |
| PCT/AU2015/050583 WO2016049694A1 (en) | 2014-09-30 | 2015-09-29 | Methods for assessing risk of developing breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529859A JP2017529859A (ja) | 2017-10-12 |
| JP2017529859A5 JP2017529859A5 (enExample) | 2018-11-08 |
| JP6820838B2 true JP6820838B2 (ja) | 2021-01-27 |
Family
ID=55629155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517098A Expired - Fee Related JP6820838B2 (ja) | 2014-09-30 | 2015-09-29 | 乳癌発症リスクを評価する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10920279B2 (enExample) |
| EP (1) | EP3201360A4 (enExample) |
| JP (1) | JP6820838B2 (enExample) |
| KR (1) | KR102334702B1 (enExample) |
| CN (1) | CN107002138B (enExample) |
| AU (2) | AU2015327756B2 (enExample) |
| CA (1) | CA2962691C (enExample) |
| IL (1) | IL251376B (enExample) |
| MX (1) | MX392267B (enExample) |
| SG (1) | SG11201702416YA (enExample) |
| WO (1) | WO2016049694A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2468901B1 (en) | 2005-11-29 | 2017-04-05 | Cambridge Enterprise Limited | Markers for breast cancer |
| DK2438193T3 (en) | 2009-06-01 | 2015-10-19 | Genetic Technologies Ltd | Methods for assessing the risk of breast cancer |
| CA2962691C (en) | 2014-09-30 | 2023-05-23 | Genetic Technologies Limited | Methods for assessing risk of developing breast cancer |
| US20200102617A1 (en) * | 2017-01-24 | 2020-04-02 | Genetic Technologies Limited | Improved Methods For Assessing Risk of Developing Breast Cancer |
| US12577622B2 (en) | 2017-06-02 | 2026-03-17 | Myriad Genetics, Inc. | Detecting cancer risk |
| CA3078756A1 (en) * | 2017-10-13 | 2019-04-18 | Genetic Technologies Limited | Methods of assessing risk of developing breast cancer |
| CN108060229A (zh) * | 2017-12-27 | 2018-05-22 | 沃森克里克（北京）生物科技有限公司 | 一种TERT基因rs10069690位点SNP核酸质谱检测方法 |
| CN110628912A (zh) * | 2019-11-06 | 2019-12-31 | 上海韦翰斯生物医药科技有限公司 | 检测多态性的引物及方法 |
| KR102169699B1 (ko) * | 2019-12-27 | 2020-10-23 | 주식회사 클리노믹스 | 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법 |
| KR20230019872A (ko) * | 2020-05-27 | 2023-02-09 | 지네틱 테크놀로지스 리미티드 | 코로나바이러스 감염에 대한 중증 반응의 발생 위험을 평가하는 방법 |
| CN112687330A (zh) * | 2020-12-29 | 2021-04-20 | 北京易奇科技有限公司 | 一种乳腺癌患者携带胚系致病变异的风险预测系统 |
| CN114283883B (zh) * | 2021-12-27 | 2022-11-22 | 上海华测艾普医学检验所有限公司 | 基于分子标记的用于肝癌筛查和风险预测的系统及应用 |
| US20250149176A1 (en) * | 2023-11-08 | 2025-05-08 | Optum Services (Ireland) Limited | Model-based risk prediction and treatment pathway prioritization |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54147035A (en) | 1978-05-10 | 1979-11-16 | Minolta Camera Co Ltd | Tessar type photographic lens placed behind aperture |
| US4240608A (en) | 1979-11-02 | 1980-12-23 | Acf Industries, Incorporated | Controlled float seat arrangement for expanding gate valves |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| WO1995011995A1 (en) | 1993-10-26 | 1995-05-04 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| JP4540754B2 (ja) | 1996-06-04 | 2010-09-08 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | Ｐｃｒ中のハイブリダイゼーションのモニタリング |
| AU723400B2 (en) | 1996-11-07 | 2000-08-24 | Oklahoma Medical Research Foundation | Diagnostic assay for breast cancer susceptibility |
| MXPA01005513A (es) | 1998-12-02 | 2003-07-14 | Dna Sciences Inc | Metodos para reducir la variacion en estudios de tratamiento utilizando genotipificacion. |
| US20020123095A1 (en) | 1999-10-20 | 2002-09-05 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
| EP1305446A4 (en) | 2000-07-25 | 2004-10-06 | Dz Genes Llc | DIAGNOSIS OF ECNOS PROMOTER POLYMORPHISMS |
| US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20030092019A1 (en) | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| AU785425B2 (en) | 2001-03-30 | 2007-05-17 | Genetic Technologies Limited | Methods of genomic analysis |
| AU2002322775A1 (en) | 2001-07-27 | 2003-02-17 | The Regents Of The University Of California | Stk15 (stk6) gene polymorphism and methods of determining cancer risk |
| US7529685B2 (en) | 2001-08-28 | 2009-05-05 | Md Datacor, Inc. | System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data |
| EP2135960A1 (en) | 2001-09-19 | 2009-12-23 | Intergenetics Incorporated | Genetic analysis for stratification of cancer risk by determining the allelic profile of the VDR-ApaI and CYP11B2 genes |
| US20040023237A1 (en) | 2001-11-26 | 2004-02-05 | Perelegen Sciences Inc. | Methods for genomic analysis |
| US6897025B2 (en) | 2002-01-07 | 2005-05-24 | Perlegen Sciences, Inc. | Genetic analysis systems and methods |
| US7135286B2 (en) | 2002-03-26 | 2006-11-14 | Perlegen Sciences, Inc. | Pharmaceutical and diagnostic business systems and methods |
| US7427480B2 (en) | 2002-03-26 | 2008-09-23 | Perlegen Sciences, Inc. | Life sciences business systems and methods |
| US20040210400A1 (en) | 2003-01-27 | 2004-10-21 | Perlegen Sciences, Inc. | Analysis methods for individual genotyping |
| US20040191783A1 (en) | 2003-03-31 | 2004-09-30 | Guy Leclercq | Low density micro-array analysis in human breast cancer |
| US20050019787A1 (en) | 2003-04-03 | 2005-01-27 | Perlegen Sciences, Inc., A Delaware Corporation | Apparatus and methods for analyzing and characterizing nucleic acid sequences |
| US7124033B2 (en) | 2003-04-30 | 2006-10-17 | Perlegen Sciences, Inc. | Method for identifying matched groups |
| US20040229224A1 (en) | 2003-05-13 | 2004-11-18 | Perlegen Sciences, Inc. | Allele-specific expression patterns |
| US20040241657A1 (en) | 2003-05-28 | 2004-12-02 | Perlegen Sciences, Inc. | Liver related disease compositions and methods |
| WO2005014846A2 (en) * | 2003-07-24 | 2005-02-17 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| WO2005024067A2 (en) | 2003-09-04 | 2005-03-17 | Intergenetics, Inc. | Genetic analysis for stratification of breast cancer risk |
| US20090087854A1 (en) | 2007-09-27 | 2009-04-02 | Perlegen Sciences, Inc. | Methods for genetic analysis |
| US7127355B2 (en) | 2004-03-05 | 2006-10-24 | Perlegen Sciences, Inc. | Methods for genetic analysis |
| EP2468901B1 (en) | 2005-11-29 | 2017-04-05 | Cambridge Enterprise Limited | Markers for breast cancer |
| CA2656199A1 (en) | 2006-06-23 | 2007-12-27 | Intergenetics, Inc. | Genetic models for stratification of cancer risk |
| US20080131887A1 (en) | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| EP2137324A2 (en) | 2007-03-26 | 2009-12-30 | Decode Genetics EHF | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
| JP2010527603A (ja) | 2007-05-25 | 2010-08-19 | ディコーデ ジェネテクス イーエイチエフ | 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのＣＨＲ５ｐ１２および１０ｑ２６上の遺伝的変異 |
| CA2693783A1 (en) | 2007-07-11 | 2009-01-15 | Intergenetics, Inc. | Genetic models for stratification of cancer risk |
| WO2009097270A2 (en) * | 2008-01-28 | 2009-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of determining breast cancer risk |
| KR20110053995A (ko) | 2008-08-08 | 2011-05-24 | 네이비제닉스 인크. | 개인별 활동 계획을 위한 방법 및 체계 |
| GB2477868A (en) | 2008-09-12 | 2011-08-17 | Navigenics Inc | Methods and systems for incorporating multiple environmental and genetic risk factors |
| DK2438193T3 (en) | 2009-06-01 | 2015-10-19 | Genetic Technologies Ltd | Methods for assessing the risk of breast cancer |
| CA2766210A1 (en) * | 2009-06-25 | 2010-12-29 | Yale University | Single nucleotide polymorphisms in brca1 and cancer risk |
| WO2013151413A1 (en) * | 2012-04-02 | 2013-10-10 | Infovalley Life Science Sdn. Bhd. | Methods and compositions for determining increased risk for breast cancer |
| CA2962691C (en) | 2014-09-30 | 2023-05-23 | Genetic Technologies Limited | Methods for assessing risk of developing breast cancer |
| US20200102617A1 (en) | 2017-01-24 | 2020-04-02 | Genetic Technologies Limited | Improved Methods For Assessing Risk of Developing Breast Cancer |
| US10609708B1 (en) | 2017-06-27 | 2020-03-31 | Sprint Spectrum L.P. | Use of TDD special subframe for transmission of small quantity of data |
| CA3078756A1 (en) | 2017-10-13 | 2019-04-18 | Genetic Technologies Limited | Methods of assessing risk of developing breast cancer |
-
2015
- 2015-09-29 CA CA2962691A patent/CA2962691C/en active Active
- 2015-09-29 US US15/515,826 patent/US10920279B2/en not_active Expired - Fee Related
- 2015-09-29 EP EP15847907.1A patent/EP3201360A4/en not_active Withdrawn
- 2015-09-29 WO PCT/AU2015/050583 patent/WO2016049694A1/en not_active Ceased
- 2015-09-29 MX MX2017004127A patent/MX392267B/es unknown
- 2015-09-29 AU AU2015327756A patent/AU2015327756B2/en not_active Ceased
- 2015-09-29 IL IL251376A patent/IL251376B/en unknown
- 2015-09-29 CN CN201580063966.2A patent/CN107002138B/zh not_active Expired - Fee Related
- 2015-09-29 KR KR1020177014480A patent/KR102334702B1/ko not_active Expired - Fee Related
- 2015-09-29 JP JP2017517098A patent/JP6820838B2/ja not_active Expired - Fee Related
- 2015-09-29 SG SG11201702416YA patent/SG11201702416YA/en unknown
-
2016
- 2016-04-19 US US15/133,055 patent/US10683549B2/en active Active
-
2018
- 2018-03-29 AU AU2018202299A patent/AU2018202299B9/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN107002138A (zh) | 2017-08-01 |
| AU2018202299A1 (en) | 2018-04-26 |
| CN107002138B (zh) | 2022-06-14 |
| AU2015327756A1 (en) | 2017-04-13 |
| US10683549B2 (en) | 2020-06-16 |
| US20180305764A1 (en) | 2018-10-25 |
| EP3201360A1 (en) | 2017-08-09 |
| MX2017004127A (es) | 2017-10-24 |
| IL251376B (en) | 2022-09-01 |
| AU2018202299B9 (en) | 2020-03-05 |
| US10920279B2 (en) | 2021-02-16 |
| EP3201360A4 (en) | 2018-05-09 |
| CA2962691A1 (en) | 2016-04-07 |
| WO2016049694A1 (en) | 2016-04-07 |
| IL251376A0 (en) | 2017-05-29 |
| JP2017529859A (ja) | 2017-10-12 |
| AU2015327756B2 (en) | 2018-01-04 |
| KR20170063977A (ko) | 2017-06-08 |
| SG11201702416YA (en) | 2017-04-27 |
| US20160222469A1 (en) | 2016-08-04 |
| MX392267B (es) | 2025-03-24 |
| CA2962691C (en) | 2023-05-23 |
| AU2018202299B2 (en) | 2019-10-24 |
| KR102334702B1 (ko) | 2021-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6820838B2 (ja) | 乳癌発症リスクを評価する方法 | |
| JP7126704B2 (ja) | 結腸直腸癌発症のリスクを評価するための方法 | |
| JP2020508643A (ja) | 乳癌発症リスクの改良された評価法 | |
| AU2022279367A1 (en) | Methods of assessing risk of developing breast cancer | |
| AU2022407711A1 (en) | Breast cancer risk assessment | |
| HK40001097A (en) | Methods for assessing risk of developing colorectal cancer | |
| HK40001097B (en) | Methods for assessing risk of developing colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180928 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191017 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200622 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201022 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201022 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201029 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201030 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201209 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210105 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6820838 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |